Bridging Gaps and Advancing Care in Sickle Cell Disease in the Context of Drug Therapy

Statement of Need

Sickle cell disease (SCD) is a pathology caused by a mutative hemoglobin protein that produces rigid, sickle-shaped red blood cells (RBCs). Lifelong complications of SCD include acute veno-occlusive crises (VOCs), whose recurrence takes a significant toll on patients, and end-organ damage. Decreased life expectancy and negative quality of life further burden a patient population that is chiefly comprised of Black individuals. Clinicians in collaboration with a multidisciplinary care team must become knowledgeable on best practices for treating patients with SCD, especially as treatment options largely remain limited to acute crises management.

In this CME Outfitters live webcast, expert faculty will elucidate the importance of comprehensive therapeutic and supportive care in preventing end-organ damage and improving QoL in patients with SCD. Learners will be guided through determining the effectiveness and challenges of current therapies to address the burden of disease in patients with SCD. Faculty will discuss emerging options in SCD treatment, including the long-term efficacy and safety of new interventions and investigational agents.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Identify the importance of comprehensive team-based therapeutic and supportive care in preventing end-organ damage and improving QoL in patients with SCD
Assess the effectiveness and challenges of current therapies to address the burden of disease in patients with SCD
Evaluate future directions in SCD treatment including combination therapies, long-term efficacy and safety studies of new interventions, and investigational agents

Financial Support

Supported by an educational grant from Novo Nordisk, Inc.

Target Audience

Hematologists and sickle cell center allied HCPs (nurse practitioners [NPs], physician associates [PAs], nurses, pharmacists, community health workers, community-based organization leaders)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.5

CME Outfitters, LLC, designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 1.5

This application-based activity is approved for 1.50 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007185-0000-24-103-L01-P).

Nurses (ANCC) 1.5

This activity is designated for 1.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Interprofessional (IPCE) 1.5

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.

Physician Assistants (AAPA): 1.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Saraf reports the following financial relationships:

Advisory Board: Agios Pharmaceuticals, Inc.; Beam Therapeutics; Chiesi USA, Inc.; CSL Behring; Novartis; Novo Nordisk and Pfizer Inc./Global Blood Therapeutics, Inc.

Research Support: Agios Pharmaceuticals, Inc.; Fulcrum Therapeutics; Novartis; Novo Nordisk; and Pfizer Inc./Global Blood Therapeutics, Inc.

Ms. Bloomberg reports the following financial relationships:

Advisory Board: Genentech, Inc.; Novo Nordisk; Pfizer Inc.; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: Bayer; Genentech, Inc.; Novo Nordisk; and Sanofi

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD  (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Chelsey Goins, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

WC-090

Bridging Gaps and Advancing Care in Sickle Cell Disease in the Context of Drug Therapy

Faculty

Statement of Need

Learning Objectives

Financial Support

Target Audience